SCHEMBL2746955

SCHEMBL2746955

CNC(=O)c1cc2c(Oc3ccc4c(C(=O)O)cccc4c3)ccnc2cc1OC

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 20/20 0.82
AURKA O14965 11/20 0.82
TEK Q02763 11/20 0.82
MET P08581 10/20 0.82
AURKB Q96GD4 10/20 0.82
LCK P06239 8/20 0.82
LYN P07948 4/20 0.67
FLT1 P17948 3/20 0.67
FGFR1 P11362 2/20 0.67
FGFR2 P21802 2/20 0.67
FLT4 P35916 2/20 0.67
ABL1 P00519 2/20 0.67
PDXK O00764 1/20 0.67
RIPK2 O43353 1/20 0.67
RET P07949 1/20 0.67
PDGFRB P09619 1/20 0.67
FGFR3 P22607 1/20 0.67
DDR1 Q08345 1/20 0.67
DDR2 Q16832 1/20 0.67
FGR P09769 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2747562 0.90 KDR (1.00) KDRAURKATEKMETAURKB
SCHEMBL29258970 0.90 KDR (0.85) KDRAURKATEKMETAURKB
SCHEMBL2747032 0.89 KDR (0.82) KDRAURKATEKMETAURKB
SCHEMBL30097451 0.89 KDR (0.90) KDRAURKATEKMETAURKB
SCHEMBL2747776 0.89 KDR (0.90) KDRAURKATEKMETAURKB
Hydrochloric Acid SCHEMBL2746794 0.88 KDR (0.81) KDRAURKATEKMETAURKB
SCHEMBL2746969 0.88 KDR (0.86) KDRAURKATEKMETAURKB
SCHEMBL4556272 0.88 KDR (0.86) KDRAURKATEKMETAURKB
SCHEMBL382398 0.86 KDR (0.87) KDRAURKATEKMETAURKB
SCHEMBL5774867 0.85 KDR (0.83) KDRAURKATEKMETAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-20060241115-A1 Compounds and methods of use AMGEN INC. 2006-10-26 US disclosed
EP-1713484-A2 COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2006-10-25 EP disclosed
WO-2005070891-A2 COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2005-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241115-A1 Compounds and methods of use HGF, HGFAC, MET KDR 354/4885AURKA 4148/4885TEK 184/4885
US-20090176774-A1 Compounds and methods of use HGF, HGFAC, MET KDR 354/4885AURKA 4148/4885TEK 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.